umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 31, nr 5, s. 1108-1116Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56(bright) NK cells had decreased relapse free survival. In addition, the TNF-α/IFN-γ cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.

Ort, förlag, år, upplaga, sidor
2017. Vol. 31, nr 5, s. 1108-1116
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:umu:diva-128517DOI: 10.1038/leu.2016.360ISI: 000400464800009PubMedID: 27890936OAI: oai:DiVA.org:umu-128517DiVA, id: diva2:1052404
Tillgänglig från: 2016-12-06 Skapad: 2016-12-06 Senast uppdaterad: 2018-06-09Bibliografiskt granskad

Open Access i DiVA

fulltext(2056 kB)162 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2056 kBChecksumma SHA-512
02c5c5d42721f0c16bfbebb1feb07855aa84afe1f0ee0bf5152b650abe9bbb1925cb040d2e6da09522c2a3c0faba28c5dc4a078883ce89897951933a5cb97e48
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Själander, Anders

Sök vidare i DiVA

Av författaren/redaktören
Själander, Anders
Av organisationen
Medicin
I samma tidskrift
Leukemia
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 162 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 127 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf